Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 379Neoplasms 336Carcinoma, Non-Small-Cell Lung 297Prostatic Neoplasms 250Colorectal Neoplasms 223Lung Neoplasms 195Multiple Myeloma 155Ovarian Neoplasms 142Pancreatic Neoplasms 140Neoplasm Metastasis 132Leukemia, Myeloid, Acute 129Melanoma 112Squamous Cell Carcinoma of Head and Neck 96Lymphoma 89Carcinoma, Renal Cell 89Stomach Neoplasms 87Recurrence 87Lymphoma, Non-Hodgkin 86Endometrial Neoplasms 85Brain Neoplasms 83Carcinoma, Hepatocellular 82Precursor Cell Lymphoblastic Leukemia-Lymphoma 81Head and Neck Neoplasms 73Glioma 73Glioblastoma 73Uterine Cervical Neoplasms 71Sarcoma 69Urinary Bladder Neoplasms 67Hematologic Neoplasms 66Leukemia, Lymphocytic, Chronic, B-Cell 65

Interventions

Taxes 1Paclitaxel 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Cyclophosphamide 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Adenocarcinoma × 30 days × Clear all
NCT00433511 2026-05-29

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
4,994 enrolled 11 charts
Breast

Breast Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡